[go: up one dir, main page]

MX2009011312A - Regimen de vacunacion para vacunas de celulas b. - Google Patents

Regimen de vacunacion para vacunas de celulas b.

Info

Publication number
MX2009011312A
MX2009011312A MX2009011312A MX2009011312A MX2009011312A MX 2009011312 A MX2009011312 A MX 2009011312A MX 2009011312 A MX2009011312 A MX 2009011312A MX 2009011312 A MX2009011312 A MX 2009011312A MX 2009011312 A MX2009011312 A MX 2009011312A
Authority
MX
Mexico
Prior art keywords
treatment
cell vaccines
hapten
vaccination regimen
specific
Prior art date
Application number
MX2009011312A
Other languages
English (en)
Inventor
Martin Bachmann
Patrik Maurer
Philipp Mueller
Thomas Pfister
Wolfgang Renner
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38669515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009011312(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of MX2009011312A publication Critical patent/MX2009011312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se relaciona con el campo de la vacunación, y el tratamiento o la prevención de enfermedades. En particular, esta invención se relaciona con el tratamiento o la prevención de enfermedades mediante la inducción de respuestas de los anticuerpos específicos contra los haptenos en un sujeto vacunado. Además, la invención proporciona un método de prevención o tratamiento de una enfermedad mediante la inducción de anticuerpos específicos contra los haptenos en un sujeto, que comprende la administración a dicho sujeto de una composición que comprende una partícula de tipo viral (Virus-Like Particle, VLP) de un bacteriófago de ARN y, al menos, un hapteno enlazado a la misma.
MX2009011312A 2007-04-20 2008-04-18 Regimen de vacunacion para vacunas de celulas b. MX2009011312A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07106676A EP1982729A1 (en) 2007-04-20 2007-04-20 Vaccination Regimen for B-Cell Vaccines
PCT/EP2008/054775 WO2008129020A1 (en) 2007-04-20 2008-04-18 Vaccination regimen for b-cell vaccines

Publications (1)

Publication Number Publication Date
MX2009011312A true MX2009011312A (es) 2009-11-05

Family

ID=38669515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011312A MX2009011312A (es) 2007-04-20 2008-04-18 Regimen de vacunacion para vacunas de celulas b.

Country Status (12)

Country Link
US (2) US20100119540A1 (es)
EP (2) EP1982729A1 (es)
JP (1) JP2010524901A (es)
CN (1) CN101678097A (es)
AU (1) AU2008240670A1 (es)
BR (1) BRPI0810088A2 (es)
CA (1) CA2683520A1 (es)
CL (1) CL2008001113A1 (es)
MX (1) MX2009011312A (es)
RU (1) RU2009142690A (es)
TW (1) TW200902058A (es)
WO (1) WO2008129020A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
DK1524994T3 (da) * 2002-07-19 2011-08-15 Cytos Biotechnology Ag Vaccinesammensætninger indeholdende amyloid beta 1-6-antigen-arrays
WO2011150264A2 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
MX373641B (es) 2011-04-29 2020-05-04 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para la terapia contra alergias.
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04012010A (es) * 2002-07-18 2005-03-07 Cytos Biotechnology Ag Conjugados de hapteno-portador que comprende particulas similares a virus, y usos de los mismos.
MXPA04006617A (es) * 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
US20060111271A1 (en) * 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
US7547712B2 (en) * 2006-02-27 2009-06-16 Nabi Biopharmaceuticals Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women
EP1849780A1 (en) * 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation

Also Published As

Publication number Publication date
RU2009142690A (ru) 2011-05-27
CN101678097A (zh) 2010-03-24
EP2148699A1 (en) 2010-02-03
CL2008001113A1 (es) 2008-12-19
JP2010524901A (ja) 2010-07-22
EP1982729A1 (en) 2008-10-22
WO2008129020A1 (en) 2008-10-30
CA2683520A1 (en) 2008-10-30
US20100119540A1 (en) 2010-05-13
BRPI0810088A2 (pt) 2014-10-21
TW200902058A (en) 2009-01-16
US20120258130A1 (en) 2012-10-11
AU2008240670A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
MX2021008224A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
EP4523756A3 (en) Immunotherapeutic vaccine and antibody combination therapy
WO2008112344A3 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
PH12016500040A1 (en) Pcsk9 vaccine
IN2014DN08830A (es)
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
MX2013004817A (es) Enfermedad inflamatoria.
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
IN2012DN02736A (es)
MX337723B (es) Vacuna de peptido ch3 de ige.
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MA32819B1 (fr) Vaccin combine notamment contre la coqueluche acellulaire
WO2009135199A3 (en) Vaccine compositions and methods
UA114286C2 (uk) Спосіб лікування staphylococcus aureus
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
MX2009011312A (es) Regimen de vacunacion para vacunas de celulas b.
HK1211980A1 (en) Multifunctional oral vaccine based on chromosome recombineering
EA201170569A1 (ru) Лекарственное средство для повышения дозы противоаллергической вакцины
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2008067995A8 (en) Means and method for raising improved immune response
WO2009117365A3 (en) Vaccine compositions for inducing immune responses against components of drusen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal